human,cervical

HPV16 E7 (86-93) acetate is a derived peptide of human leukocyte antigen A2.1 restricted HPV16 E7 with immunogenic property in cervical carcinomas.

VIP(6-28)(human, rat, porcine, bovine) acetate is an antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) receptor on cAMP in the superior cervical ganglion (SCG).

Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) serves both as a substrate-specific peptide inhibitor of MLCK and as an inhibitor of hypotonicity-induced Ca2+ entry. This compound has applications in the research of human cervical cancer [1] [2].

HPV16 E7 (86-93) TFA, a peptide derived from HPV16 E7, is restricted by human leukocyte antigen (HLA)-A2.1 and exhibits immunogenic properties in cervical carcinomas [1] [2].

This is amino acids 86 to 93 fragment of the human papilloma virus (HPV) type 16 oncoprotein E7. This HPV16-encoded peptide has very high affinity of binding to the HLA-A*0201 molecule.This immunogenic fragment may be used in vaccines for the prevention a

BRC4wt, an acetylated peptide originating from the BRC4 repeat within human BRCA2 (1521-1536), acts as an inhibitor of the BRCA2 and RAD51 protein-protein interaction. When linked to the cationic cell-penetrating peptide (Arg)9, it effectively shortens DNA replication tract lengths and diminishes the frequency of homologous repair of camptothecin-induced DNA damage in vitro. Additionally, BRC4wt enhances the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib in inducing cell death in HeLa human cervical cancer and U2OS human osteosarcoma cells, albeit it does not affect non-cancerous hTERT RPE-1, MRC-5, or MCF-10A cells.